July 19, 2025

FacebookTwitterInstagramYouTube
  • Home
  • Events
  • NEWS
    • Top Stories
    • National News
    • National Sports
  • Current Contests
  • Photos/Video
    • Photos
    • Videos
  • On-Air
    • Kat & Ku`ehu
    • G. Cruz
    • Kaohu James
  • Podcasts
    • KWXX Mauna Loa Eruption Updates
    • Island Conversations
    • COVID-19 Interview
  • Contact
  • Info
  • Search
  • FCC Applications
MENU
  • Home
  • Events
  • NEWS
    • Top Stories
    • National News
    • National Sports
  • Current Contests
  • Photos/Video
    • Photos
    • Videos
  • On-Air
    • Kat & Ku`ehu
    • G. Cruz
    • Kaohu James
  • Podcasts
    • KWXX Mauna Loa Eruption Updates
    • Island Conversations
    • COVID-19 Interview
  • Contact
  • Info
  • Search
  • FCC Applications

NIH seeking volunteers for an antibody clinical trial

August 23, 2020 at 7:54 am sbracken
  • Blogs
  • Covid-19
  • Tweet
  • Share
  • Reddit
  • +1
  • Pocket
  • LinkedIn

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is going to start a clinical trial, and is seeking volunteers who are currently infected with SARS-CoV-2, the virus which causes COVID-19, who have mild to moderate disease not requiring hospitalization.

The Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of antibodies to treat the disease.  The approximately 220 patients will take the experimental drug or a placebo as part of a rigorous randomized clinical trial.

If the Phase 2 portion goes well, the study will move to a Phase 3 trial with around 2,000 participants.  The study team wants to enroll patients from around the world.

The first therapeutic to be tested in this trial will be an antibody manufactured in a lab, starting with blood from a recovered COVID-19 patient, given via infusion to the volunteers.  The antibody is made by Eli Lilly and Company, headquartered in Indianapolis, Indiana,  in partnership with  AbCellera Biologics, headquartered in Vancouver, British Columbia.

COVID-19 patients often have low blood oxygen levels, so one part of the trial will be to see if the therapeutic has a positive effect on blood oxygen levels.  A goal is to see if the trial drug reduces hospitalization and deaths from COVID-19.

“Using an antibody generated by the immune system of a recovered COVID-19 patient gives us a jump start on finding a safe and effective therapeutic,” said NIAID Director Anthony S. Fauci, M.D. “Investigating a variety of different therapeutics, including monoclonal antibodies, will help ensure that we advance towards an effective treatment for people suffering from COVID-19 disease as quickly as possible.”

The effort is a public-private partnership and is also receiving support as part of the Federal Government’s “Operation Warp Speed” to quickly develop vaccines and treatments.

Click here for more on the trial.

 

 

Tags: COVID-19 antibody trial, COVID-19 treatment
Previous Story
COVID: world and US on steady climb–Hawaii positive rate climbs
Next Story
Hawaii County reports 12 new, 48 active active COVID-19 cases

Facebook

Twitter

Tweets by KWXX

"Hawaii's Feel Good Island Music Radio Station"

Info

  • Home
  • Contests
  • Socialize
  • Contact Us
  • Station Info
  • EEO
  • FCC Public File (KWXX)
  • FCC Public File (KAOY)

National News

President Donald Trump walks across the south lawn after stepping off Marine 1 Washington DC^ United States^ April 6 2025

Pres. Trump undergoes testing for swelling in legs, diagnosed with chronic venou...

Four lightning bolt strike during a thunderstorm on Long Beach Island^ NJ.

1 killed, 13 injured by lightning strike at archery range in New Jersey

Social

Facebook Facebook Twitter Twitter Instagram Instagram YouTube YouTube
KWXX – Hilo, HI © 2025 Powered by OneCMS™ | Served by InterTech Media LLC
Are you still listening?
3628718134
Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)
b2440a530371987d1bb9bf13b2678468d6aba867
1
Loading...